001     136865
005     20240229105104.0
024 7 _ |a 10.1200/JCO.2017.75.9308
|2 doi
024 7 _ |a pmid:29746225
|2 pmid
024 7 _ |a pmc:PMC6075859
|2 pmc
024 7 _ |a 0732-183X
|2 ISSN
024 7 _ |a 1527-7755
|2 ISSN
024 7 _ |a altmetric:40991490
|2 altmetric
037 _ _ |a DKFZ-2018-01303
041 _ _ |a eng
082 _ _ |a 050
100 1 _ |a Hoffman, Lindsey M
|b 0
245 _ _ |a Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries.
260 _ _ |a Alexandria, Va.
|c 2018
|b American Society of Clinical Oncology
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1659947718_8495
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Purpose Diffuse intrinsic pontine glioma (DIPG) is a brainstem malignancy with a median survival of < 1 year. The International and European Society for Pediatric Oncology DIPG Registries collaborated to compare clinical, radiologic, and histomolecular characteristics between short-term survivors (STSs) and long-term survivors (LTSs). Materials and Methods Data abstracted from registry databases included patients from North America, Australia, Germany, Austria, Switzerland, the Netherlands, Italy, France, the United Kingdom, and Croatia. Results Among 1,130 pediatric and young adults with radiographically confirmed DIPG, 122 (11%) were excluded. Of the 1,008 remaining patients, 101 (10%) were LTSs (survival ≥ 2 years). Median survival time was 11 months (interquartile range, 7.5 to 16 months), and 1-, 2-, 3-, 4-, and 5-year survival rates were 42.3% (95% CI, 38.1% to 44.1%), 9.6% (95% CI, 7.8% to 11.3%), 4.3% (95% CI, 3.2% to 5.8%), 3.2% (95% CI, 2.4% to 4.6%), and 2.2% (95% CI, 1.4% to 3.4%), respectively. LTSs, compared with STSs, more commonly presented at age < 3 or > 10 years (11% v 3% and 33% v 23%, respectively; P < .001) and with longer symptom duration ( P < .001). STSs, compared with LTSs, more commonly presented with cranial nerve palsy (83% v 73%, respectively; P = .008), ring enhancement (38% v 23%, respectively; P = .007), necrosis (42% v 26%, respectively; P = .009), and extrapontine extension (92% v 86%, respectively; P = .04). LTSs more commonly received systemic therapy at diagnosis (88% v 75% for STSs; P = .005). Biopsies and autopsies were performed in 299 patients (30%) and 77 patients (10%), respectively; 181 tumors (48%) were molecularly characterized. LTSs were more likely to harbor a HIST1H3B mutation (odds ratio, 1.28; 95% CI, 1.1 to 1.5; P = .002). Conclusion We report clinical, radiologic, and molecular factors that correlate with survival in children and young adults with DIPG, which are important for risk stratification in future clinical trials.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Veldhuijzen van Zanten, Sophie E M
|b 1
700 1 _ |a Colditz, Niclas
|b 2
700 1 _ |a Baugh, Joshua
|b 3
700 1 _ |a Chaney, Brooklyn
|b 4
700 1 _ |a Hoffmann, Marion
|b 5
700 1 _ |a Lane, Adam
|b 6
700 1 _ |a Fuller, Christine
|b 7
700 1 _ |a Miles, Lili
|b 8
700 1 _ |a Hawkins, Cynthia
|b 9
700 1 _ |a Bartels, Ute
|b 10
700 1 _ |a Bouffet, Eric
|b 11
700 1 _ |a Goldman, Stewart
|b 12
700 1 _ |a Leary, Sarah
|b 13
700 1 _ |a Foreman, Nicholas K
|b 14
700 1 _ |a Packer, Roger
|b 15
700 1 _ |a Warren, Katherine E
|b 16
700 1 _ |a Broniscer, Alberto
|b 17
700 1 _ |a Kieran, Mark W
|b 18
700 1 _ |a Minturn, Jane
|b 19
700 1 _ |a Comito, Melanie
|b 20
700 1 _ |a Broxson, Emmett
|b 21
700 1 _ |a Shih, Chie-Schin
|b 22
700 1 _ |a Khatua, Soumen
|b 23
700 1 _ |a Chintagumpala, Murali
|b 24
700 1 _ |a Carret, Anne Sophie
|b 25
700 1 _ |a Escorza, Nancy Yanez
|b 26
700 1 _ |a Hassall, Timothy
|b 27
700 1 _ |a Ziegler, David S
|b 28
700 1 _ |a Gottardo, Nicholas
|b 29
700 1 _ |a Dholaria, Hetal
|b 30
700 1 _ |a Doughman, Renee
|b 31
700 1 _ |a Benesch, Martin
|b 32
700 1 _ |a Drissi, Rachid
|b 33
700 1 _ |a Nazarian, Javad
|b 34
700 1 _ |a Jabado, Nada
|b 35
700 1 _ |a Boddaert, Nathalie
|b 36
700 1 _ |a Varlet, Pascale
|b 37
700 1 _ |a Giraud, Géraldine
|b 38
700 1 _ |a Castel, David
|b 39
700 1 _ |a Puget, Stephanie
|b 40
700 1 _ |a Jones, Chris
|b 41
700 1 _ |a Hulleman, Esther
|b 42
700 1 _ |a Modena, Piergiorgio
|b 43
700 1 _ |a Giagnacovo, Marzia
|b 44
700 1 _ |a Antonelli, Manila
|b 45
700 1 _ |a Pietsch, Torsten
|b 46
700 1 _ |a Gielen, Gerrit H
|b 47
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 48
|u dkfz
700 1 _ |a Sturm, Dominik
|0 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
|b 49
|u dkfz
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 50
|u dkfz
700 1 _ |a Gerber, Nicolas U
|b 51
700 1 _ |a Grotzer, Michael A
|b 52
700 1 _ |a Pfaff, Elke
|0 P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb
|b 53
|u dkfz
700 1 _ |a von Bueren, André O
|b 54
700 1 _ |a Hargrave, Darren
|b 55
700 1 _ |a Solanki, Guirish A
|b 56
700 1 _ |a Jadrijevic Cvrlje, Filip
|b 57
700 1 _ |a Kaspers, Gertjan J L
|b 58
700 1 _ |a Vandertop, William P
|b 59
700 1 _ |a Grill, Jacques
|b 60
700 1 _ |a Bailey, Simon
|b 61
700 1 _ |a Biassoni, Veronica
|b 62
700 1 _ |a Massimino, Maura
|b 63
700 1 _ |a Calmon, Raphaël
|b 64
700 1 _ |a Sanchez, Esther
|b 65
700 1 _ |a Bison, Brigitte
|b 66
700 1 _ |a Warmuth-Metz, Monika
|b 67
700 1 _ |a Leach, James
|b 68
700 1 _ |a Jones, Blaise
|b 69
700 1 _ |a van Vuurden, Dannis G
|b 70
700 1 _ |a Kramm, Christof M
|b 71
700 1 _ |a Fouladi, Maryam
|b 72
773 _ _ |a 10.1200/JCO.2017.75.9308
|g Vol. 36, no. 19, p. 1963 - 1972
|0 PERI:(DE-600)2005181-5
|n 19
|p 1963 - 1972
|t Journal of clinical oncology
|v 36
|y 2018
|x 1527-7755
909 C O |p VDB
|o oai:inrepo02.dkfz.de:136865
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 48
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 49
|6 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 50
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 53
|6 P:(DE-He78)c0538fae462bd98e3cd8d54ed885b0eb
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J CLIN ONCOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a IF >= 20
|0 StatID:(DE-HGF)9920
|2 StatID
|b J CLIN ONCOL : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21